Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-NewS: Dasatinib Discontinuation in CML
NCT01887561Phase 2Unknown
- Sponsor
- Kanto CML Study Group
- Start
- Nov 2012
- Primary completion
- Dec 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Kanto CML Study Group. Primary endpoint: Probability of maintenance of complete molecular remission after stopping dasatinib at 12 months. Status: unknown.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01887561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01887561.